TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31281056

Group type: EXPERIMENTAL
Intervention: Intraretinal hypereflective foci (IHRF)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Hyporeflective foci (hRF) within drusenoid lesions (DLs)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Subretinal drusenoid deposits (SDD)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Drusen volume (DV) of 0.03 mm3 or more
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Late AMD (defined as MNV, complete retinal pigment epithelium and photoreceptor atrophy [cRORA], or both)
Number of subjects: 501
Study: 28011155

Group type: EXPERIMENTAL
Intervention: Etanercept or adalimumab combined with methotrexate
Number of subjects: 48
Study: 25671770

Group type: EXPERIMENTAL
Intervention: S-1 (80, 100, or 120 mg day‐1 for 1 year)
Number of subjects: 505

Group type: COMPARATOR
Intervention: UFT (300 or 400 mg day‐1 for 1 year)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 505

Group type: COMPARATOR
Intervention: UFT
Number of subjects: 505
Study: 23721752

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including an initial interactive workshop and quarterly educational outreach visits focused on maternal death reviews and best practices implementation over 2 years.
Number of subjects: 191167

Group type: COMPARATOR
Intervention: Control group with no external intervention.
Number of subjects: 191167
Study: 21350053

Group type: EXPERIMENTAL
Intervention: BMI <23.5 kg/m(2)
Number of subjects: 4109

Group type: EXPERIMENTAL
Intervention: BMI ≥35 kg/m(2)
Number of subjects: 4109

Group type: COMPARATOR
Intervention: BMI 26.5 to 30.9 kg/m(2)
Number of subjects: 4109

Group type: EXPERIMENTAL
Intervention: All BMI categories
Number of subjects: 4109
Study: 19300388

Group type: EXPERIMENTAL
Intervention: Soy group (2 g of soybeans per kilogram body weight for 7 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 36
Study: 17126434

Group type: EXPERIMENTAL
Intervention: 16Gy boost radiation after 50Gy whole breast irradiation
Number of subjects: 5318

Group type: COMPARATOR
Intervention: No boost radiation after 50Gy whole breast irradiation
Number of subjects: 5318
Study: 15557666

Group type: EXPERIMENTAL
Intervention: Three-component acellular pertussis vaccine
Number of subjects: 0
Study: 11710749

Group type: EXPERIMENTAL
Intervention: Progressive ratio schedule
Number of subjects: 8

Group type: COMPARATOR
Intervention: Random sequences of ratio requirements
Number of subjects: 8
Study: 9151915

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Doxorubicin (DOX)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Doxorubicin (DOX) low-risk subgroup
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) high-risk subgroup
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) and Doxorubicin (DOX)
Number of subjects: 415
Study: 7899837

Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac and methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2776141

Group type: EXPERIMENTAL
Intervention: Flosequinan 100 mg orally once daily for 3 days
Number of subjects: 12
Study: 164510

Group type: EXPERIMENTAL
Intervention: 1 percent papaverine cream
Number of subjects: 45

Group type: COMPARATOR
Intervention: cream alone
Number of subjects: 45
Study: 30346850

Group type: EXPERIMENTAL
Intervention: RBAC (3 grams/day for 6 months)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31604081

Group type: EXPERIMENTAL
Intervention: Integrated care centers (ICCs) delivering HIV testing and HCV testing/education
Number of subjects: 11993

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11993
Study: 31146493

Group type: EXPERIMENTAL
Intervention: Slowly digestible carbohydrate (SDC) in water
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SDC drink-mix powder reconstituted in skim milk
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dextrose in water (placebo)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control drink-mix reconstituted in skim milk (without SDC)
Number of subjects: 14
Study: 27356547

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (50 µg)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Maternal total homocysteine (tHcy) levels
Number of subjects: 183
Study: 24785136

Group type: EXPERIMENTAL
Intervention: Culturally tailored educational intervention for 6 weeks (90 minutes once a week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 23084254

Group type: EXPERIMENTAL
Intervention: Supervised multimodal exercise intervention (9 hours weekly for 6 weeks)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Supervised multimodal exercise intervention
Number of subjects: 213

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 213
Study: 21288350

Group type: EXPERIMENTAL
Intervention: Grapefruit (GF) preload
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) preload
Number of subjects: 85

Group type: COMPARATOR
Intervention: Water preload
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: All preloads combined with caloric restriction
Number of subjects: 85
Study: 18849016

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) withdrawal
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: C-reactive protein concentration of 20 mg/L or greater
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hemoglobin level less than 12 g/dL
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Neutrophil count 4 x 10(9)/L or greater
Number of subjects: 66
Study: 22240283

Group type: EXPERIMENTAL
Intervention: Conatumumab-doxorubicin (doxorubicin 75 mg/m2 + conatumumab 15 mg/kg every 3 weeks)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo-doxorubicin (doxorubicin 75 mg/m2 + placebo)
Number of subjects: 128
Study: 16040577

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12423518

Group type: EXPERIMENTAL
Intervention: High-concentration platelets (HCPs) stored for 1 day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-concentration platelets (HCPs) stored for 2 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-concentration platelets (HCPs) stored for 5 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard apheresis platelets (APCs)
Number of subjects: 9
Study: 9796223

Group type: EXPERIMENTAL
Intervention: Different neighboring concepts linked to the test cue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different kinds of cues (taxonomic category names, ending sounds, meaningfully related associates)
Number of subjects: 0
Study: 8584362

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 111

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Treatment failure
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Clinical failure
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Children who failed treatment
Number of subjects: 111
Study: 2128949

Group type: EXPERIMENTAL
Intervention: 750 mg lithium carbonate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 9
Study: 652005

Group type: EXPERIMENTAL
Intervention: Donor blood containing high titer of anti-HBc but lacking HBsAg and anti-HBs; 4 patients received this blood.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (26 patients); no exposure to high titer anti-HBc blood.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients with 'immunization-like' response (9 patients); developed anti-HBs without anti-HBc.
Number of subjects: 30
Study: 11239634

Group type: EXPERIMENTAL
Intervention: Heated patch plus placebo tablet
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Unheated patch plus ibuprofen
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination heated patch plus ibuprofen
Number of subjects: 84

Group type: COMPARATOR
Intervention: Unheated patch plus placebo group
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Heated patch plus ibuprofen
Number of subjects: 84
Study: 31521161

Group type: EXPERIMENTAL
Intervention: Play-based psychomotor/psychosocial stimulation during hospital stay and at home for 6 months after discharge
Number of subjects: 339

Group type: COMPARATOR
Intervention: Routine medical care and nutritional treatment
Number of subjects: 339
Study: 30006305

Group type: EXPERIMENTAL
Intervention: Anti-T lymphocyte globulin (ATLG)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 26608054

Group type: EXPERIMENTAL
Intervention: Unilateral transverse process-pedicle PKP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bilateral PKP
Number of subjects: 56
Study: 23942869

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 22227341

Group type: EXPERIMENTAL
Intervention: Echocardiography analysis
Number of subjects: 2136
Study: 20832819

Group type: EXPERIMENTAL
Intervention: Arrhythmia monitoring
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: Ischemia monitoring
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: QT interval monitoring
Number of subjects: 1816
Study: 17369807

Group type: EXPERIMENTAL
Intervention: Nucleotide supplement (E)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 30
Study: 15903284

Group type: EXPERIMENTAL
Intervention: Pharmacist transition coordinator
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual hospital discharge process
Number of subjects: 110
Study: 11989986

Group type: EXPERIMENTAL
Intervention: Enhanced community management (ECM)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 193
Study: 9796354

Group type: EXPERIMENTAL
Intervention: Ceruletide infusion cholescintigraphy
Number of subjects: 26
Study: 7705012

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg tid
Number of subjects: 263

Group type: COMPARATOR
Intervention: Ceftazidime 1000 mg tid for RTIs and 500 mg tid for UTIs
Number of subjects: 263
Study: 2533786

Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine + multiple doses of HBIG (Group I)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine + single dose of HBIG (Group II)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine only (Group III)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Heat-inactivated hepatitis B vaccine only
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Single dose of HBIG
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Multiple doses of HBIG
Number of subjects: 235

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 235
Study: 405902

Group type: EXPERIMENTAL
Intervention: Pilocarpine in Adsorbobase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilocarpine in 0.5% hydroxypropyl-methylcellulose solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilocarpine (both formulations)
Number of subjects: 0
Study: 31590286

Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Ketogenic (VLCK) diet
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low-Calorie (LC) diet
Number of subjects: 79

Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 79
Study: 28697789

Group type: EXPERIMENTAL
Intervention: Intramuscular or intra-arterial injection of 40 ml BM-MNC concentrate
Number of subjects: 50
Study: 25483023

Group type: EXPERIMENTAL
Intervention: IDet+IAsp
Number of subjects: 403

Group type: COMPARATOR
Intervention: BIAsp1-2-3
Number of subjects: 403
Study: 23665335

Group type: EXPERIMENTAL
Intervention: HERA (Health Evaluation and Referral Assistant)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 1006
Study: 21989078

Group type: COMPARATOR
Intervention: Metformin 1 g, twice daily
Number of subjects: 159
Study: 18177701

Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement (CLF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Panavia 21 (PAN)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Variolink II (VAR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (UNI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Experimental GC self‐adhesive cement (EGC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Panavia 21 (PAN), Clearfil Esthetic Cement (CLF), Variolink II (VAR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: RelyX Unicem (UNI), Experimental GC self‐adhesive cement (EGC)
Number of subjects: 50
Study: 16467423

Group type: EXPERIMENTAL
Intervention: Frontal eye fields (FEFs) activity during response selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraparietal sulcus (IPS) activity during response selection
Number of subjects: 0
Study: 14586213

Group type: EXPERIMENTAL
Intervention: Bryostatin-1 25 mug/m(2) as a 1-h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bryostatin-1 120 mug/m(2) as a 72-h continuous infusion every 2 weeks (Regimen II)
Number of subjects: 70
Study: 10587284

Group type: EXPERIMENTAL
Intervention: Haloperidol 25 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Haloperidol 25 mg/day + Lithium
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg/day + Lorazepam 4 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Haloperidol 25 mg/day + Lorazepam 4 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Haloperidol 5 mg/day + Placebo
Number of subjects: 63
Study: 8727681

Group type: EXPERIMENTAL
Intervention: Repeated traumatic pictorial stimuli (combat related pictures)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Target stimuli (domestic animal pictures)
Number of subjects: 40
Study: 1659980

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg intravenously before chemotherapy, with up to two further doses daily of 40 micrograms/kg if necessary)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Alizapride plus dexamethasone (4 mg/kg alizapride and 8 mg/kg dexamethasone before chemotherapy, repeated if necessary after 4 and 8 hours up to two additional doses)
Number of subjects: 115
Study: 6119558

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1943
Study: 30968327

Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvre (RM) with positive end-expiratory pressure (PEEP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (without RM)
Number of subjects: 19
Study: 31806191

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Bare Metal Stents (BMS)
Number of subjects: 1200
Study: 28752157

Group type: EXPERIMENTAL
Intervention: Resin sealants
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Glass-carbomer sealants
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer ART sealants with heat application
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer ART sealants without heat application
Number of subjects: 405
Study: 26340571

Group type: EXPERIMENTAL
Intervention: Brief Intervention Training for alcohol problems (16 hours duration)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 120
Study: 23179254

Group type: EXPERIMENTAL
Intervention: Posturography-assisted vestibular rehabilitation protocol (30 min a week) combined with home-based exercise program (Group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Home-based exercise program alone (Group B)
Number of subjects: 28
Study: 20816833

Group type: EXPERIMENTAL
Intervention: formoterol/beclomethasone 12/200 μg Modulite
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: formoterol/budesonide 9/320 μg Turbuhaler
Number of subjects: 28

Group type: COMPARATOR
Intervention: formoterol alone
Number of subjects: 28
Study: 18204873

Group type: EXPERIMENTAL
Intervention: Dual molecular weight (DMW; 580-780 kDa + 1.2 to 2.0 million Da)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low molecular weight (LMW; 500-730 kDa)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High molecular weight (HMW; 6 million Da)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 200
Study: 16416322

Group type: EXPERIMENTAL
Intervention: Balance program (12 weeks, 3 times per week, 20 min per session) before soccer training (TxB group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Balance program (12 weeks, 3 times per week, 20 min per session) after soccer training (TxA group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 39
Study: 12838857

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemotherapy and radiotherapy (A group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Radiotherapy and chemotherapy (B group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Simple radiotherapy (C group)
Number of subjects: 87
Study: 10849191

Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg/day plus dipyridamole 75 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day plus placebo
Number of subjects: 30
Study: 9020945

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg IV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Granisetron plus methylprednisolone (250 mg IV)
Number of subjects: 20
Study: 7937272

Group type: EXPERIMENTAL
Intervention: Specialized enteral formula (supplemental arginine, linolenic acid, beta-carotene, hydrolyzed protein for up to 10 days)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Specialized enteral formula
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 41
Study: 3335879

Group type: EXPERIMENTAL
Intervention: Internal Consistency Analysis (ICA)
Number of subjects: 0
Study: 29302875

Group type: EXPERIMENTAL
Intervention: Bacon sham feeding
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 122
Study: 27504014

Group type: EXPERIMENTAL
Intervention: 6-month, culturally tailored, U.S. Diabetes Prevention Program-based lifestyle curriculum plus stepwise addition of metformin (500 mg, twice daily)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Standard lifestyle advice (control)
Number of subjects: 578
Study: 25616353

Group type: EXPERIMENTAL
Intervention: study-quiz group
Number of subjects: 96

Group type: COMPARATOR
Intervention: quiz group
Number of subjects: 96
Study: 22801006

Group type: EXPERIMENTAL
Intervention: Interpretation training to endorse positive interpretations of mildly negative and positive social events
Number of subjects: 153

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Interpretation training
Number of subjects: 153
Study: 20973984

Group type: EXPERIMENTAL
Intervention: Pre-completion incentive (book token)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Post-completion incentive (promise of a book token)
Number of subjects: 591

Group type: COMPARATOR
Intervention: No incentive (nothing at all)
Number of subjects: 591
Study: 17465700

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (20 mg/day) for 12 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no atorvastatin treatment)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (20 mg/day)
Number of subjects: 29
Study: 16810279

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 100
Study: 11926936

Group type: EXPERIMENTAL
Intervention: Residential crisis program
Number of subjects: 119

Group type: COMPARATOR
Intervention: General hospital psychiatric unit
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 119
Study: 9476862

Group type: EXPERIMENTAL
Intervention: Sodium 4-phenylbutyrate (Buphenyl) 19 grams p.o. divided t.i.d. for 1 week
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7542142

Group type: EXPERIMENTAL
Intervention: Adjuvant preoperative radiotherapy and operation
Number of subjects: 284

Group type: COMPARATOR
Intervention: Surgical operation alone
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Adjuvant preoperative radiotherapy
Number of subjects: 284
Study: 2197911

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (600 mg by inhalation using a Respirgard II nebulizer)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous pentamidine (3 mg/kg body weight administered once daily for 2 to 3 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous pentamidine
Number of subjects: 45
Study: 265082

Group type: EXPERIMENTAL
Intervention: Topical painting with potassium fluoride solution containing Al-, Fe-, and Mn-ions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical painting with 0.2% NaF-solution
Number of subjects: 0
Study: 7044620

Group type: EXPERIMENTAL
Intervention: Oestrogen/gestagen alone or in combination with 1,25(OH)2D3
Number of subjects: 74

Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 74

Group type: COMPARATOR
Intervention: 1,25(OH)2D3
Number of subjects: 74
Study: 30683164

Group type: EXPERIMENTAL
Intervention: Meaning‐Centered Grief Therapy (MCGT)
Number of subjects: 11
Study: 29394367

Group type: EXPERIMENTAL
Intervention: Symptomatic falciparum malaria patients on Day 0 (D0)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Symptomatic falciparum malaria patients in recrudescent phase (Drec)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Asymptomatic Plasmodium vivax carriers
Number of subjects: 109

Group type: COMPARATOR
Intervention: Asymptomatic falciparum carriers
Number of subjects: 109